Elite in Glomerulonephritis

Nicolas Maillard

Lyon, FR 
Elite in Glomerulonephritis
Lyon, FR 
OverviewLocationsClinical Research

Overview

Nicolas Maillard practices in Lyon, France. Mr. Maillard is rated as an Elite expert by MediFind in the treatment of Glomerulonephritis. His top areas of expertise are IgA Nephropathy, Glomerulonephritis, Chronic Kidney Disease, Kidney Transplant, and Bone Marrow Transplant.

His clinical research consists of co-authoring 90 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 25 articles and participated in 2 clinical trials in the study of Glomerulonephritis.

Gender
Male

Locations

Lyon, France
Other Locations
Saint-etienne-de-valoux, France
Strasbourg, France
Besancon, France
Reims, France
France
Vannes, 56000, France
Saint-jean-saint-germain, France
Bordeaux, 33000, France
Caen, France
2, Rue De La Milétrie, Poitiers, 86000, France
University Hospital of St Etienne
Saint-etienne, France
Rennes, France
Nantes, France
Angers, France
Saint-priest-la-vetre, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Impact of the Use of Remote Monitoring in the Follow-up of the Renal Transplant Patient.
Impact of the Use of Remote Monitoring in the Follow-up of the Renal Transplant Patient.
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 3
Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients
Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients
Enrollment Status: Completed
Publish Date: September 24, 2021
Intervention Type: Drug
Study Drug: Period with Drug and Period with Generic (ALDACTONE, FLUMACH, SPIROCTAN, SPIRONONE, FLUDEX, INDATEN, LASILIX, TENSTATEN, ALDACTAZINE, PRINACTIZIDE, SPIROCTAZINE, MODURETIC, AVLOCARDYL, HEMIPRALON, STHASIN, BETATOP, TENORMINE, CELECTOL, DETENSIEL, FELSAN, KERLONE, RAGON, RONALOL, LOPRESSOR, SELOKEN, NEBILOX, TEMERIT, NEVEROL, SECTRAL, ACUITEL, KOREC, BRIEM, CIBACENE, COVERSYL, CAPTOLANE, LOPRIL, FOZITEC, ODRIK, GOPTEN, PRINIVIL, ZESTRIL, RENITEC, TEOULA, ZOFENIL, TRIATEC, KENOMON, ADALATE, CHRONOADALATE, AMLOR, BAYPRESS, DELTAZEN, DILRENE, DIACOR, MONO TILDIEM, FLODIL, IPERTEN, ISOPTINE, LERCAN, ZANIDIP, LEDELCARBERDIPE, LENIBERCARDIPE, DIBERLEPIDINE, XILERMIS, APROVEL, CRISARTERS, IFIRMASTA, FLUPPE, ZELMIRB, ATACAND, KENZEN, KARBIS, COZAAR, LOBERASNAT, LOTANBERSAR, MICARDIS, PRITOR, TOLURA, ZANACODAR, DINORTES, MIRPRESOC, NISIS, TAREG, CUENCA, TIFIVAL, VAGRECOR, VAMADRID, HYPERIUM, PHYSIOTENS, BIPRETERAX, PRETERAX, LODOZ, WYTENS, ACUILIX, KORETIC, BRIAZIDE, CIBADREX, CAPTEA, ECAZIDE, CORENITEC, ENALAVIS, ENALURETIC, COTRIATEC, RADOUCHE, FOZIRETIC, PRINZIDE, ZESTORETIC, COAPROVEL, IFIRMACOMBI, COCRISARTERS, COKENZEN, HYTACAND, COANHYVA, COHESAN , COTAREG, NISISCO, FORTZAAR, HYZAAR, MICARDISPLUS, PRITORPLUS, MARESSI, TOLUCOMBI, TENORDATE, BETA ADALATE)
Study Phase: Phase 4
Platelet-associated Inflammation in Severe Sepsis
Platelet-associated Inflammation in Severe Sepsis
Enrollment Status: Completed
Publish Date: July 10, 2020
Intervention Type: Other
Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy
Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy
Enrollment Status: Completed
Publish Date: January 25, 2017
Intervention Type: Biological
Study Phase: Not Applicable
View 4 Less Clinical Trials

90 Total Publications

Early Change in Proteinuria as a Surrogate Endpoint in Studies of IgA Nephropathy: An Updated Patient-Level Meta-analysis and Discussion of Appropriate Methodology.
Early Change in Proteinuria as a Surrogate Endpoint in Studies of IgA Nephropathy: An Updated Patient-Level Meta-analysis and Discussion of Appropriate Methodology.
Journal: Advances in therapy
Published: September 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Maillard's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile